2024
TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial
Everson R, Hugo W, Sun L, Antonios J, Lee A, Ding L, Bu M, Khattab S, Chavez C, Billingslea-Yoon E, Salazar A, Ellingson B, Cloughesy T, Liau L, Prins R. TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial. Nature Communications 2024, 15: 3882. PMID: 38719809, PMCID: PMC11078958, DOI: 10.1038/s41467-024-48073-y.Peer-Reviewed Original ResearchConceptsAutologous tumor lysate-pulsed dendritic cellCD8+ T cellsT cellsPoly-ICLCTLR agonistsMalignant gliomasTumor lysate-pulsed dendritic cellsRandomized phase II trialCD4+ T cellsRandomized phase II clinical trialInterferon responsePhase II clinical trialPoly-ICLC treatmentDendritic cell vaccinesPD-1 expressionPhase II trialInterferon responsive gene expressionSystemic immune responsesImmune cell activationII clinical trialsInduction of interferon-inducible genesDelay disease progressionInterferon gene expressionInterferon-inducible genesPD-1
2018
Cell-Based Immunotherapy of Gliomas
Everson R, Antonios J, Liau L. Cell-Based Immunotherapy of Gliomas. Progress In Neurological Surgery 2018, 32: 90-100. PMID: 29990977, DOI: 10.1159/000469683.Peer-Reviewed Original ResearchConceptsCellular immunotherapyImmune cellsDendritic cell (DC)-based vaccinesTreatment of malignant gliomasCellular immunotherapy approachesAntitumor immune cellsAntitumor responseAdoptive transferImmunotherapy approachesActive immunotherapyLive immune cellsMalignant gliomasEffector capabilitiesPassive immunotherapyImmunotherapyImmune responseEx vivoImmune systemGlioma cellsCell typesPatientsGliomaCellsNeoplasms
2016
TCR Sequencing Can Identify and Track Glioma-Infiltrating T Cells after DC Vaccination
Hsu M, Sedighim S, Wang T, Antonios J, Everson R, Tucker A, Du L, Emerson R, Yusko E, Sanders C, Robins H, Yong W, Davidson T, Li G, Liau L, Prins R. TCR Sequencing Can Identify and Track Glioma-Infiltrating T Cells after DC Vaccination. Cancer Immunology Research 2016, 4: 412-418. PMID: 26968205, PMCID: PMC4873445, DOI: 10.1158/2326-6066.cir-15-0240.Peer-Reviewed Original ResearchConceptsTumor-infiltrating lymphocytesT cell receptorT-cell receptor sequencingImmune responseOverall survivalPeripheral bloodIncreased time to progressionTumour-infiltrating lymphocytes contentAssessment of tumor-infiltrating lymphocytesPredictors of immune responseAntigen-specific immune responsesTime to progressionDendritic cell immunotherapyDC vaccinesCell immunotherapyImmunotherapeutic strategiesSurvival outcomesStatistically significant correlationT cellsClinical outcomesAdjunctive treatmentBrain tumorsImmunotherapyNext-generation sequencing approachTumor
2015
Dendritic cell immunotherapy for brain tumors
Antonios J, Everson R, Liau L. Dendritic cell immunotherapy for brain tumors. Journal Of Neuro-Oncology 2015, 123: 425-432. PMID: 26037466, DOI: 10.1007/s11060-015-1830-1.Peer-Reviewed Original ResearchConceptsDendritic cellsPatient-derived dendritic cellsDestruction of malignant cellsDendritic cell immunotherapyGlioma treatmentPre-clinical modelsCell immunotherapyDC vaccinesTreatment of gliomaActive immunotherapyProlonged survivalMalignant cellsImmunological targetsPatient-specific treatmentClinical trialsImmune responseTherapeutic approachesBrain tumorsBrain parenchymaGliomaImmunotherapyTreatmentBrainCellsImmunosuppression